Skip to main content

Characterization of molecular mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea alone or in combination with O-6-benzylguanine in human medulloblastoma and rhabdomyosarcoma cell lines.

Publication ,  Journal Article
Bacolod, MD; Bullock, NH; Johnson, SP; Colvin, OM; Friedman, HS
Published in: CLINICAL CANCER RESEARCH
November 1, 2001

Duke Scholars

Published In

CLINICAL CANCER RESEARCH

ISSN

1078-0432

Publication Date

November 1, 2001

Volume

7

Issue

11

Start / End Page

3739S / 3739S

Publisher

AMER ASSOC CANCER RESEARCH

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bacolod, M. D., Bullock, N. H., Johnson, S. P., Colvin, O. M., & Friedman, H. S. (2001). Characterization of molecular mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea alone or in combination with O-6-benzylguanine in human medulloblastoma and rhabdomyosarcoma cell lines. CLINICAL CANCER RESEARCH, 7(11), 3739S-3739S.
Bacolod, M. D., N. H. Bullock, S. P. Johnson, O. M. Colvin, and H. S. Friedman. “Characterization of molecular mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea alone or in combination with O-6-benzylguanine in human medulloblastoma and rhabdomyosarcoma cell lines.CLINICAL CANCER RESEARCH 7, no. 11 (November 1, 2001): 3739S-3739S.
Bacolod MD, Bullock NH, Johnson SP, Colvin OM, Friedman HS. Characterization of molecular mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea alone or in combination with O-6-benzylguanine in human medulloblastoma and rhabdomyosarcoma cell lines. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2001 Nov 1;7(11):3739S-3739S.

Published In

CLINICAL CANCER RESEARCH

ISSN

1078-0432

Publication Date

November 1, 2001

Volume

7

Issue

11

Start / End Page

3739S / 3739S

Publisher

AMER ASSOC CANCER RESEARCH

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis